19 June 2013
Keywords: bayer, rises, fda, panel, recommends, xarelto, post-surgery
Article | 30 March 2009
An expert panel convened by the US Food and Drug Administration has recommended Bayer's Xarelto (rivaroxaban) for approval. Shares in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
30 March 2009
© 2013 thepharmaletter.com